cGFS
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Everett H Meyer, Amandeep Salhotra, Arpita P Gandhi, Jeremy Pantin, Sagar S Patel, Rasmus T Hoeg, Alexandra Gomez-Arteaga, Rawan Faramand, Roni Tamari, Edmund K Waller, Satyajit Kosuri, Antonio M Jimenez Jimenez, Jennifer Holter-Chakrabarty, Bhagirathbhai Dholaria, Yi-Bin Chen, Betty K Hamilton, John Magenau, Alireza Eghtedar, Joshua M Murray, Anna Pavlova, Nathaniel B Fernhoff, James Scott McClellan, M Scott Killian, Ai Li, Robert S Negrin, Caspian Oliai
Blood 147(11) 1168-1177
To prevent graft-versus-host disease (GVHD) in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT), a calcineurin inhibitor plus methotrexate is routinely used. Early phase studies suggested improved outcomes with Orca-T, an allogeneic T-cell immunotherapy that uses purified donor regulatory T cells to prevent GVHD with significantly less immunosuppression. This phase 3 trial randomized adult patients (N = 187) with acute leukemias or myelodysplastic syndrome undergoing myeloablative conditioning to receive either Orca-T with tacrolimus or a conventional allograft with tacrolimus and methotrexate (Tac/MTX), using granulocyte colony-stimulating factor-mobilized peripheral blood from HLA-matched donors. The primary end point was survival free from moderate-to-severe chronic GVHD (cGVHD; cGFS). Using a stratified log-rank test, cGFS was significantly higher in the Orca-T arm than in Tac/MTX (hazard ratio, 0.26; 95% confidence interval, 0.14-0.47; P< .001). One-year estimates were as follows: cGFS was 78.0% with Orca-T vs 38.4% with Tac/MTX; cumulative incidence of moderate-to-severe cGVHD was 12.6% with Orca-T and 44.0% with Tac/MTX (Gray test P< .001); overall survival was 93.9% with Orca-T vs 83.1% with Tac/MTX (P = .12); GVHD-free and relapse-free survival was 63.1% and 30.9% in the Orca-T and Tac/MTX arms (P< .001), respectively; nonrelapse mortality (NRM) was 3.4% with Orca-T vs 13.2% with Tac/MTX (P = .03). Orca-T met the primary end point of improved survival free from cGVHD compared with Tac/MTX prophylaxis and should be considered a new therapeutic option with low toxicity for GVHD prophylaxis. Moreover, significantly less toxicity was observed with Orca-T patients, including fewer serious infectious complications and less NRM. This trial was registered at www.clinicaltrials.gov as NCT05316701.
1 个 Figure · 4 个 KM 面板
Figure 2. Survival probabilities and the cumulative incidence of primary and secondary end point events. (A) The cGFS (the primary end point) after Orca-T or Tac/MTX prophylaxis over 1 year. The shaded areas indicate 95% simultaneous confidence bands. (B) The cumulative incidence of moderate-to-severe cGVHD over 1 year. (C) The OS probability over 1 year. (D) The survival free from grade 3 to 4 acute GVHD, moderate-to-severe cGVHD, or relapse (GRFS) over 1 year. For the estimates of the secondary end point events, 95% CIs for survival and cumulative incidence at 1 year (panels B-D) are provided, but they have not been adjusted for multiplicity and should not be used for hypothesis testing.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel C
Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel D
Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。